Xtant Leadership|Restructuring Monday, November 16, 2026 -0.30 Negative

Xtant Reports Q3 Results, Announces Board-led Strategic Review

Xtant reported lower Q3 revenue but up 11% biologics performance, prompting the Board to initiate a strategic review of alternatives to maximize value and improve execution.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed